199 related articles for article (PubMed ID: 12910578)
1. Pulmonary mucus: Pediatric perspective.
Rogers DF
Pediatr Pulmonol; 2003 Sep; 36(3):178-88. PubMed ID: 12910578
[TBL] [Abstract][Full Text] [Related]
2. Treatment of airway mucus hypersecretion.
Rogers DF; Barnes PJ
Ann Med; 2006; 38(2):116-25. PubMed ID: 16581697
[TBL] [Abstract][Full Text] [Related]
3. Airway mucus hypersecretion in asthma: an undervalued pathology?
Rogers DF
Curr Opin Pharmacol; 2004 Jun; 4(3):241-50. PubMed ID: 15140415
[TBL] [Abstract][Full Text] [Related]
4. Current and future therapies for airway mucus hypersecretion.
Barnes PJ
Novartis Found Symp; 2002; 248():237-49; discussion 249-53, 277-82. PubMed ID: 12568498
[TBL] [Abstract][Full Text] [Related]
5. Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy.
Lai HY; Rogers DF
Curr Opin Allergy Clin Immunol; 2010 Feb; 10(1):67-76. PubMed ID: 19907312
[TBL] [Abstract][Full Text] [Related]
6. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
7. Mucin-producing elements and inflammatory cells.
Jeffery P; Zhu J
Novartis Found Symp; 2002; 248():51-68; discussion 68-75, 277-82. PubMed ID: 12568488
[TBL] [Abstract][Full Text] [Related]
8. New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.
Lai H; Rogers DF
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):219-31. PubMed ID: 20695774
[TBL] [Abstract][Full Text] [Related]
9. Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy.
Rogers DF
Monaldi Arch Chest Dis; 2000 Aug; 55(4):324-32. PubMed ID: 11057087
[TBL] [Abstract][Full Text] [Related]
10. Physiology of airway mucus secretion and pathophysiology of hypersecretion.
Rogers DF
Respir Care; 2007 Sep; 52(9):1134-46; discussion 1146-9. PubMed ID: 17716382
[TBL] [Abstract][Full Text] [Related]
11. Effects of concentrated ambient particles on normal and hypersecretory airways in rats.
Harkema JR; Keeler G; Wagner J; Morishita M; Timm E; Hotchkiss J; Marsik F; Dvonch T; Kaminski N; Barr E
Res Rep Health Eff Inst; 2004 Aug; (120):1-68; discussion 69-79. PubMed ID: 15543855
[TBL] [Abstract][Full Text] [Related]
12. Non-allergic models of mucous cell metaplasia and mucus hypersecretion in rat nasal and pulmonary airways.
Harkema JR; Wagner JG
Novartis Found Symp; 2002; 248():181-97; discussion 197-200, 277-82. PubMed ID: 12568495
[TBL] [Abstract][Full Text] [Related]
13. Airway hypersecretion in allergic rhinitis and asthma: new pharmacotherapy.
Rogers DF
Curr Allergy Asthma Rep; 2003 May; 3(3):238-48. PubMed ID: 12662474
[TBL] [Abstract][Full Text] [Related]
14. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Respir Care; 2002 Jul; 47(7):818-22. PubMed ID: 12088552
[TBL] [Abstract][Full Text] [Related]
15. Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases.
Ha EV; Rogers DF
Pharmacology; 2016; 97(1-2):84-100. PubMed ID: 26674354
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis.
Simpson JL; Phipps S; Gibson PG
Pharmacol Ther; 2009 Oct; 124(1):86-95. PubMed ID: 19555716
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
Mata M; Sarriá B; Buenestado A; Cortijo J; Cerdá M; Morcillo EJ
Thorax; 2005 Feb; 60(2):144-52. PubMed ID: 15681504
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of the tyrosine kinase signaling cascade for asthma.
Wong WS
Curr Opin Pharmacol; 2005 Jun; 5(3):264-71. PubMed ID: 15907913
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats.
Ou XM; Wang BD; Wen FQ; Feng YL; Huang XY; Xiao J
Chin Med J (Engl); 2008 Sep; 121(17):1680-7. PubMed ID: 19024099
[TBL] [Abstract][Full Text] [Related]
20. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
